- Home
- BMRA vs NCNA Comparison
BMRA vs NCNA Comparison
Compare BMRA & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRA
- NCNA
- Stock Information
- Founded
- BMRA 1971
- NCNA 1997
- Country
- BMRA United States
- NCNA United Kingdom
- Employees
- BMRA N/A
- NCNA N/A
- Industry
- BMRA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- BMRA Health Care
- NCNA Health Care
- Exchange
- BMRA Nasdaq
- NCNA Nasdaq
- Market Cap
- BMRA 8.2M
- NCNA 6.6M
- IPO Year
- BMRA N/A
- NCNA 2017
- Fundamental
- Price
- BMRA $2.98
- NCNA $3.86
- Analyst Decision
- BMRA
- NCNA
- Analyst Count
- BMRA 0
- NCNA 0
- Target Price
- BMRA N/A
- NCNA N/A
- AVG Volume (30 Days)
- BMRA 470.5K
- NCNA 338.4K
- Earning Date
- BMRA 10-14-2025
- NCNA 08-20-2025
- Dividend Yield
- BMRA N/A
- NCNA N/A
- EPS Growth
- BMRA N/A
- NCNA N/A
- EPS
- BMRA N/A
- NCNA N/A
- Revenue
- BMRA $5,311,000.00
- NCNA N/A
- Revenue This Year
- BMRA N/A
- NCNA N/A
- Revenue Next Year
- BMRA N/A
- NCNA N/A
- P/E Ratio
- BMRA N/A
- NCNA N/A
- Revenue Growth
- BMRA N/A
- NCNA N/A
- 52 Week Low
- BMRA $2.08
- NCNA $2.78
- 52 Week High
- BMRA $10.16
- NCNA $1,650.00
- Technical
- Relative Strength Index (RSI)
- BMRA 45.65
- NCNA 41.45
- Support Level
- BMRA $2.74
- NCNA $2.82
- Resistance Level
- BMRA $3.08
- NCNA $3.60
- Average True Range (ATR)
- BMRA 0.23
- NCNA 0.24
- MACD
- BMRA -0.01
- NCNA 0.43
- Stochastic Oscillator
- BMRA 45.92
- NCNA 74.48
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.